Jefferies reiterates Praxis Precision Medicines stock rating on FDA review

Jefferies reiterated a Buy on Praxis Precision Medicines with a $525 price target, implying upside from the current $339.90 share price. The FDA accepted the NDA for ulixacaltamide in essential tremor and set a PDUFA date of Jan. 29, 2027, with no advisory committee expected; Jefferies assigns a 75% to 80% approval probability. The stock has already surged 966% over the past year to a $9.47 billion market cap, so the news is supportive but likely less transformative than the prior rally.

Analysis

PRAX is morphing from a single-asset biotech story into a probability-weighted regulatory event, and that changes how the stock should trade. The key second-order effect is that the long-dated PDUFA compresses the near-term catalyst path into a sequence of data presentations, KOL validation, and sentiment-driven re-ratings rather than a binary approval event, which tends to support elevated multiples for much longer than fundamentals would justify. That said, the market is already pricing a meaningful approval probability, so incremental upside now depends on whether management can expand the addressable patient pool without triggering skepticism about pricing durability or real-world adoption.

The main winner here is not just PRAX equity holders, but option sellers and event-driven longs who can monetize volatility decay over the next 12-18 months if the company keeps de-risking the asset. The main loser may be late-stage bears: when a biotech re-rates this sharply before approval, short interest can become self-reinforcing into each conference and regulatory update, but that also makes the name fragile to any signal of label narrowing, additional review, or payer pushback. The bigger hidden risk is commercialization math — a high WAC can support peak-sales models on paper, but in essential tremor the actual net revenue per patient may be far more elastic than bulls assume, especially if competitor neuro/neurology franchises decide to sharpen contracting.

Contrarian read: the stock may not be cheap even if the approval thesis is right. The market is likely discounting a clean approval path, but less attention is being paid to post-approval execution risk, neurologist uptake, and whether the initial launch profile can sustain the valuation before the 2027 decision date. In other words, the upside from approval is real, but the path to realizing it is long, and every month of delay increases the chance that valuation mean reversion, not clinical disappointment, becomes the main downside driver.

Key Decisions for Investors

• Maintain a tactical long in PRAX into upcoming data presentations, but size it as a catalyst trade rather than a fundamental compounder; target 15-25% upside on continued de-risking, with a stop if regulatory language turns more cautious.
• Use call spreads instead of outright stock for the next 3-6 months; the setup favors upside participation with limited theta bleed if the name stalls ahead of the 2027 PDUFA.
• If already long, sell a portion into strength on conference-driven pops and re-enter on post-event drift; this is a classic biotech volatility harvesting setup.
• Watch for a long/short pair versus a weaker neurology development name or basket, but only if PRAX maintains positive regulatory momentum; the relative trade works best if the market starts rewarding de-risked late-stage assets over earlier-stage peers.
• Do not chase here on a standalone basis; the risk/reward becomes less attractive if the stock remains near highs without a fresh catalyst, because multiple expansion is already doing the heavy lifting.